Mitomycin Accord Healthcare (Mitomycin)

Mitomycin is reduced inside hypoxic tumour cells to a highly reactive intermediate that forms covalent cross‑links between DNA strands. These cross‑links block DNA unwinding and replication, leading to inhibition of DNA synthesis, cell‑cycle arrest and ultimately programmed cell death of rapidly dividing cancer cells.

The dose of Mitomycin is individualized by the prescribing oncologist based on the specific cancer type, treatment regimen, patient weight, renal and hepatic function, and prior therapy. Clinicians calculate the appropriate amount and schedule according to established clinical guidelines.

Mitomycin is classified as contraindicated in pregnancy because it can cause fetal harm, including teratogenic effects and embryotoxicity. It is also excreted in breast milk, so breastfeeding is not recommended during treatment. Women of child‑bearing potential should use effective contraception while receiving the drug.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Mitomycin Accord Healthcare. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and the necessary import documentation.

Mitomycin belongs to the same class as drugs like doxorubicin and bleomycin, sharing a DNA‑targeting mechanism. Compared with some alternatives, Mitomycin has a distinct activation pathway that favours hypoxic tumour cells, which can provide therapeutic benefit in certain solid tumours. However, its toxicity profile, especially bone‑marrow suppression, may differ and influences regimen selection.

Mitomycin should be stored at 2‑8 °C in a refrigerator, protected from light, and kept in its original packaging to avoid moisture exposure. The product must not be frozen or shaken. During preparation, use aseptic technique and handle with appropriate protective equipment to prevent accidental exposure.

Mitomycin is supplied as a sterile solution for intravenous infusion or intravesical instillation. Intravenous dosing is given over a defined period, usually in a clinical setting with monitoring. For bladder cancer, the drug is instilled directly into the bladder after tumour resection and retained for a prescribed dwell time.

The most critical risks include severe bone‑marrow suppression leading to neutropenia, anemia or thrombocytopenia, which can predispose to infection and bleeding. Pulmonary toxicity such as interstitial lung disease or fibrosis, and hemolytic‑uremic syndrome are rare but life‑threatening complications that require immediate medical attention.

Mitomycin is contraindicated in patients with known hypersensitivity to the drug, severe renal or hepatic impairment, active uncontrolled infections, and in pregnant or breastfeeding women. It should also be avoided in individuals receiving live vaccines or high‑dose radiation therapy without careful risk assessment.